Novartis AG
NVS
NVS: Novartis develops and manufactures healthcare products through two business segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
moreShow NVS Financials
$NVS is featured in our Shelley Moore Capito and Tom Carper strategies.
See All StrategiesAll
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of NVS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by NVS's directors and management
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
U.S. Patents
New patents grants
-
Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Sep. 19, 2023
-
Patent Title: Dosage regimen of an s1p receptor modulator Sep. 19, 2023
-
Patent Title: Fatty acids and their use in conjugation to biomolecules Sep. 12, 2023
-
Patent Title: Compounds and compositions for treating solid tumors by intratumoral administration Sep. 12, 2023
-
Patent Title: Compounds and compositions for inducing chondrogenesis Sep. 12, 2023
-
Patent Title: Computer method and system for deriving cell-to-cell spatial proximities Sep. 05, 2023
-
Patent Title: Biomarkers predictive of cytokine release syndrome Sep. 05, 2023
-
Patent Title: Therapeutic regimen Aug. 29, 2023
-
Patent Title: Uses of piperidinyl-indole derivatives Aug. 15, 2023
-
Patent Title: Methods of treating ophthalmic disorders Aug. 15, 2023
-
Patent Title: Method of scoring a sample comprising tumor tissue Aug. 15, 2023
-
Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Aug. 15, 2023
-
Patent Title: Cell bag rotator Aug. 08, 2023
-
Patent Title: Sulphonamides and compositions thereof for treating conditions associated with nlrp activity Aug. 08, 2023
-
Patent Title: Methods for treating hematologic cancers Jul. 25, 2023
-
Patent Title: Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof Jul. 25, 2023
-
Patent Title: Pyrazolyl derivatives useful as anti-cancer agents Jul. 18, 2023
-
Patent Title: Fgf21 mimetic antibodies and uses thereof Jul. 04, 2023
-
Patent Title: Engineered heterodimeric proteins Jun. 27, 2023
-
Patent Title: Multi-dose ocular fluid delivery system Jun. 20, 2023
-
Patent Title: Carboxamide derivatives Jun. 13, 2023
-
Patent Title: Amino pyrimidine derivatives Jun. 13, 2023
-
Patent Title: 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating smn-deficiency-related conditions Jun. 13, 2023
-
Patent Title: Treatment of cancer using chimeric cd3 receptor proteins Jun. 06, 2023
-
Patent Title: Antiviral pyrazolopyridinone compounds Jun. 06, 2023
-
Patent Title: Crystalline forms of 5-bromo-2,6-di(1h-pyrazol-1- yl)pyrimidin-4-amine and new salts May. 23, 2023
-
Patent Title: Thienopyrimidinone nmda receptor modulators and uses thereof May. 16, 2023
-
Patent Title: Method for preparing a pharmaceutical product May. 09, 2023
-
Patent Title: Polyomavirus neutralizing antibodies May. 02, 2023
-
Patent Title: Anti-ccr7 antibody drug conjugates Apr. 25, 2023
-
Patent Title: Solid forms comprising an oxime ether compound, compositions and methods of use thereof Apr. 18, 2023
-
Patent Title: Parenteral formulation comprising siponimod Apr. 18, 2023
-
Patent Title: 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza Apr. 18, 2023
-
Patent Title: Substituted pyrrolo[2,3-d]pyrimidines as bruton's tyrosine kinase inhibitors Mar. 28, 2023
-
Patent Title: Injector device Mar. 21, 2023
-
Patent Title: Bcma chimeric antigen receptors and uses thereof Mar. 21, 2023
-
Patent Title: Crystalline form of lnp023 Mar. 14, 2023
-
Patent Title: Compounds and compositions for the treatment of parasitic diseases Mar. 07, 2023
-
Patent Title: Specific sites for modifying antibodies to make immunoconjugates Mar. 07, 2023
-
Patent Title: Compounds and compositions for treating conditions associated with nlrp activity Mar. 07, 2023
-
Patent Title: Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same Feb. 28, 2023
-
Patent Title: Treatment of cancer using a cd123 chimeric antigen receptor Feb. 28, 2023
-
Patent Title: Chemical process for preparing phenylpiperidinyl indole derivatives Feb. 14, 2023
-
Patent Title: Stable and soluble antibodies inhibiting tnfα Feb. 14, 2023
-
Patent Title: Regulatable chimeric antigen receptor Feb. 14, 2023
-
Patent Title: 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof Jan. 31, 2023
-
Patent Title: Injection device and injection solution transferring system Jan. 17, 2023
-
Patent Title: 2-azaspiro[3.4]octane derivatives as m4 agonists Jan. 10, 2023
-
Patent Title: Cell secreted minibodies and uses thereof Jan. 10, 2023
-
Patent Title: Crystalline forms of a triazolopyrimidine compound Jan. 10, 2023
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on NVS's company Twitter account
WallStreetBets
Number of mentions of NVS in WallStreetBets Daily Discussion
NVS News
Recent insights relating to NVS
CNBC Recommendations
Recent picks made for NVS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in NVS
Corporate Flights
Flights by private jets registered to NVS